BioAge Labs, Inc. (BIOA)

BioAge Labs Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022
Net Income	-75.79	-71.11	-63.85	-39.72
Depreciation & Amortization	0.19	0.17	0.16	0.13
Loss (Gain) From Sale of Assets	0.06	0.06	-	-
Stock-Based Compensation	11.69	6.98	3.02	2.54
Other Operating Activities	-0.15	1.21	16.6	0.08
Change in Accounts Payable	2.97	0.01	-0.39	0.99
Change in Unearned Revenue	8.06	9.19	3.31	-
Change in Other Net Operating Assets	-5.03	1.98	3.79	-0.2
Operating Cash Flow	-58.51	-51.52	-37.36	-36.18
Capital Expenditures	-0.63	-0.37	-0.17	-0.1
Investment in Securities	-80.18	-	-0.1	-
Investing Cash Flow	-80.81	-0.37	-0.27	-0.1
Short-Term Debt Issued	-	-	23.5	-
Long-Term Debt Issued	-	-	12.5	2.5
Total Debt Issued	-	-	36	2.5
Long-Term Debt Repaid	-	-6	-1	-
Net Debt Issued (Repaid)	-6	-6	35	2.5
Issuance of Common Stock	27.65	222.25	0	0.04
Other Financing Activities	-1.29	-5.05	-0.06	-0.05
Financing Cash Flow	20.36	381.2	34.94	2.5
Foreign Exchange Rate Adjustments	0.07	0.08	-	0.25
Net Cash Flow	-118.9	329.39	-2.69	-33.54
Free Cash Flow	-59.15	-51.89	-37.53	-36.28
Free Cash Flow Per Share	-1.65	-4.84	-22.43	-21.70
Cash Interest Paid	0.8	1.42	1.16	0.13
Levered Free Cash Flow	-41.48	-34.21	-27.91	-
Unlevered Free Cash Flow	-40.9	-32.73	-23.04	-
Change in Working Capital	5.49	11.18	6.71	0.8

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q